Hemostatic effects of three colloid plasma substitutes for priming solution in cardiopulmonary bypass

被引:30
|
作者
Tigchelaar, I [1 ]
Huet, RCGG [1 ]
Korsten, J [1 ]
Boonstra, PW [1 ]
vanOeveren, W [1 ]
机构
[1] UNIV GRONINGEN HOSP,NL-9712 KZ GRONINGEN,NETHERLANDS
关键词
cardiopulmonary bypass; hemostasis; plasma substitute;
D O I
10.1016/S1010-7940(96)01059-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To evaluate the effects on hemostasis of three different plasma substitutes with special reference to a newly developed hydroxyethyl starch used as priming solution in an extracorporeal circuit as well as peri- and postoperative infusion fluid, we studied 36 patients randomly assigned to one of three groups, undergoing coronary artery bypass grafting. Methods: The compositions of the priming solutions were: 2.5% hydroxyethyl starch; 3% gelatin; and 4% human albumin. Platelet function tests and clotting assays were performed on blood samples collected during and after cardiopulmonary bypass. Results: We found that plasma von Willebrand Factor remained higher in the human albumin group. Hydroxyethyl starch preserved platelet agglutination as well as human albumin, whereas platelet aggregation induced by adenosine 5'-di phosphate (ADP) proved to be similarly affected during cardiopulmonary bypass in thr three study groups. Prolongation of the in vitro bleeding constant during the bypass period and subsequent partial recovery showed an affected platelet function in all groups during cardiopulmonary bypass. The dotting times, activated partial thromboplastin time and prothrombin time were similar in the three groups. Bloodless, peri- and postoperatively, showed also no differences. Hydroxyethyl starch appeared most cost-effective as priming solution in an extracorporeal circuit. Conclusions: We conclude that, with human albumin the golden standard, 2.5% hydroxyethyl starch is a suitable colloid plasma substitute to be used as priming solution in an extracorporeal circuit as well as peri- and postoperative infusion fluid, reasonably well maintaining hemostasis. (C) 1997 Elsevier Science B.V.
引用
收藏
页码:626 / 632
页数:7
相关论文
共 50 条
  • [1] HEMODILUTION WITH A PLASMA EXPANDER AS PRIMING SOLUTION IN CARDIOPULMONARY BYPASS
    MOYES, DG
    SOUTH AFRICAN MEDICAL JOURNAL, 1974, 48 (38): : 1615 - 1616
  • [2] Hemostatic effects of a dextran-based priming solution for cardiopulmonary bypass: A secondary analysis of a randomized clinical trial
    Barbu, Mikael
    Kolsrud, Oscar
    Radulovic, Vladimir
    Dellgren, Goran
    Bjork, Kerstin
    Thoren, Anders
    Pivodic, Aldina
    Ricksten, Sven -Erik
    Jeppsson, Anders
    THROMBOSIS RESEARCH, 2023, 223 : 139 - 145
  • [3] Effects of crystalloid and colloid priming strategies for cardiopulmonary bypass on colloid oncotic pressure and haemostasis: a meta-analysis
    Beukers, Anne Maria
    de Ruijter, Jamy Adriana Catharina
    Loer, Stephan Alexander
    Vonk, Alexander
    Bulte, Carolien Suzanna Enna
    INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2022, 35 (03)
  • [4] HEMODYNAMIC, METABOLIC, AND MORPHOLOGICAL EFFECTS OF CARDIOPULMONARY BYPASS WITH A FLUOROCARBON PRIMING SOLUTION
    STONE, JJ
    PICCIONE, W
    BERRIZBEITIA, LD
    DANCE, GR
    SCHOEN, FJ
    SHEMIN, RJ
    COHN, LH
    ANNALS OF THORACIC SURGERY, 1986, 41 (04): : 419 - 424
  • [5] Priming solution for neonatal and pediatric cardiopulmonary bypass
    Pouard, P.
    IRBM, 2010, 31 : S27 - S30
  • [6] Comparison of three plasma expanders used as priming fluids in cardiopulmonary bypass patients
    Tigchelaar, Izaak
    Huet, Rolf C. G. Gallandat
    Boonstra, Piet W.
    van Oeveren, Willem
    PERFUSION-UK, 1998, 13 (05): : 297 - 303
  • [7] PULMONARY OXYGENATION, CENTRAL HEMODYNAMICS AND GLOMERULAR-FILTRATION FOLLOWING CARDIOPULMONARY BYPASS WITH COLLOID OR NON-COLLOID PRIMING SOLUTION
    OHQVIST, G
    SETTERGREN, G
    LUNDBERG, S
    SCANDINAVIAN JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1981, 15 (03): : 257 - 262
  • [8] HYDROXYETHYL STARCH (HES) AS A PRIMING SOLUTION IN CARDIOPULMONARY BYPASS
    GURBUZ, A
    BERKI, T
    AKINCI, E
    KOCAK, T
    YAKUT, C
    VASCULAR SURGERY, 1991, 25 (04): : 308 - 314
  • [9] EFFECTS OF APROTININ ON HEMOSTATIC MECHANISMS DURING CARDIOPULMONARY BYPASS
    VANOEVEREN, W
    JANSEN, NJG
    BIDSTRUP, BP
    ROYSTON, D
    WESTABY, S
    NEUHOF, H
    WILDEVUUR, CRH
    ANNALS OF THORACIC SURGERY, 1987, 44 (06): : 640 - 645
  • [10] BENEFITS OF A GLUCOSE-CONTAINING PRIMING SOLUTION FOR CARDIOPULMONARY BYPASS
    METZ, S
    KEATS, AS
    ANESTHESIA AND ANALGESIA, 1991, 72 (04): : 428 - 434